GATE
Marblegate Acquisition Corp. Class A Common Stock
stock NASDAQ

This short rigged $2.25B Baby Bio is about to Release Phase 3 Registrational Trial results for a Revolutionary Immunotherapy for AML remission maintenance, giving Gps the FDA Green Light to a $28B Total Addressable Market - worth every nickel of $50B to big pharma.
Do the Math: Load As many as you can.
Your future self will thank you.
• Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients
• 12,500 Patients 34/36 Month Median OS
• 3 Year Dosing Regime
• Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3
• 80% Patient Uptake Rates --- Just shy of $5B in Revenue
• Then ADD in 40,000 AML CR1 Patients Each Year
• 5 year Dosing
• +100,000 AML Patients Currently In Remission right now, who'll benefit from Gps Immunotherapy, right out of the GATE.

This short rigged $2.25B Baby Bio is about to Release Phase 3 Registrational Trial results for a Revolutionary Immunotherapy for AML remission maintenance, giving Gps the FDA Green Light to a $28B Total Addressable Market - worth every nickel of $50B to big pharma.
Do the Math: Load As many as you can.
Your future self will thank you.
• Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients
• 12,500 Patients 34/36 Month Median OS
• 3 Year Dosing Regime
• Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3
• 80% Patient Uptake Rates --- Just shy of $5B in Revenue
• Then ADD in 40,000 AML CR1 Patients Each Year
• 5 year Dosing
• +100,000 AML Patients Currently In Remission right now, who'll benefit from Gps Immunotherapy, right out of the GATE.